Gilead Sciences (NASDAQ:GILD) Price Target Increased to $100.00 by Analysts at JPMorgan Chase & Co.

Gilead Sciences (NASDAQ:GILD) had its target price upped by JPMorgan Chase & Co. from $95.00 to $100.00 in a report released on Wednesday morning, Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on the company. Cantor Fitzgerald restated a neutral rating and set a $70.00 target price on shares of Gilead Sciences in a report on Monday, September 16th. Truist Financial raised their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a hold rating in a research report on Thursday, August 15th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an outperform rating in a research report on Friday, August 9th. Needham & Company LLC restated a hold rating on shares of Gilead Sciences in a report on Thursday, August 15th. Finally, Evercore ISI upgraded Gilead Sciences to a strong-buy rating in a report on Friday, August 9th. Ten investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of Moderate Buy and an average target price of $84.83.

Gilead Sciences Trading Up 0.3 %

Shares of GILD opened at $84.95 on Wednesday. The stock has a market capitalization of $105.84 billion, a P/E ratio of 235.97, a PEG ratio of 2.98 and a beta of 0.18. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $87.86. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The firm has a fifty day simple moving average of $79.87 and a two-hundred day simple moving average of $72.34.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. On average, research analysts anticipate that Gilead Sciences will post 3.78 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.63%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock worth $3,033,340 over the last 90 days. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GILD. Manning & Napier Advisors LLC purchased a new stake in Gilead Sciences during the 2nd quarter valued at $25,328,000. Legal & General Group Plc lifted its holdings in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after acquiring an additional 93,068 shares during the period. GSA Capital Partners LLP purchased a new position in Gilead Sciences in the first quarter worth about $462,000. Brookstone Capital Management grew its stake in shares of Gilead Sciences by 751.1% during the 1st quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock valued at $9,322,000 after purchasing an additional 112,305 shares during the period. Finally, Comerica Bank increased its position in shares of Gilead Sciences by 10.7% during the 4th quarter. Comerica Bank now owns 329,990 shares of the biopharmaceutical company’s stock valued at $26,733,000 after purchasing an additional 31,849 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.